Raven Biotechnologies advances RAV18 through agreement with CMC ICOS Biologics
17-Mar-2008 -
Raven biotechnologies, Inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer and CMC ICOS Biologics, Inc. a contract manufacturing organization, announced they have entered into an agreement under which CMC ICOS will create a ...
antibodies
biology
cancer stem cells
+4